
|Videos|October 15, 2017
Who Will Benefit from the Darunavir Single-Tablet Regimen for HIV?
Author(s)Contagion® Editorial Staff
Magda Opsomer, MD, reveals who will benefit from the darunavir single-tablet HIV regimen.
Advertisement
Magda Opsomer, MD, director and clinical leader of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies, Belgium, reveals who will benefit from the darunavir single-tablet HIV regimen.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
The Potential Ramifications of Changing the MMR Vaccine Into 3 Separate Immunizations
2
How New “Shared Clinical Decision Making” Vaccine Category Will Likely Increase Children’s Disease
3
Cascading Effects of Executive Order on Childhood Vaccines
4
This Week's Top 5 Infectious Disease News Stories: August 8-August 14, 2026
5



























































































































































